- Home
- MVBF vs INBX Comparison
MVBF vs INBX Comparison
Compare MVBF & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MVBF | INBX |
|---|---|---|
| Founded | 1997 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 351.9M | 430.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MVBF | INBX |
|---|---|---|
| Price | $27.67 | $88.53 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 2 |
| Target Price | ★ $27.60 | N/A |
| AVG Volume (30 Days) | 83.3K | ★ 245.4K |
| Earning Date | 10-29-2025 | 11-14-2025 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | ★ 73.99 | N/A |
| EPS | ★ 2.45 | N/A |
| Revenue | ★ $167,853,000.00 | $1,400,000.00 |
| Revenue This Year | N/A | $563.00 |
| Revenue Next Year | $14.06 | $230.77 |
| P/E Ratio | $11.17 | ★ N/A |
| Revenue Growth | ★ 18.75 | N/A |
| 52 Week Low | $15.59 | $10.81 |
| 52 Week High | $28.96 | $94.47 |
Technical Indicators
Market Signals| Indicator | MVBF | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 52.63 | 58.68 |
| Support Level | $26.52 | $74.80 |
| Resistance Level | $28.96 | $94.47 |
| Average True Range (ATR) | 0.81 | 6.40 |
| MACD | 0.03 | -1.07 |
| Stochastic Oscillator | 48.31 | 59.63 |
Price Performance
Historical ComparisonAbout MVBF MVB Financial Corp.
MVB Financial Corp is a bank holding company. The company provides Personal banking, Business banking, and Fintech solutions. The group has identified three reportable segments: CoRe Banking, Mortgage Banking, and Financial Holding Company. The majority of ts revenue generated from the CoRe Banking segment, which includes the Fintech division, represents banking products and services offered to customers by the Bank, loans, and deposit accounts. Revenue from banking activities consists of interest earned on loans and investment securities and service charges on deposit accounts.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.